Hosted on MSN4d
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Nektar Therapeutics NKTR incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks ...
FiercePharma8d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...
Nektar presents late-breaking results from Phase 2 Study of NKTR-255
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
FiercePharma5d
Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
The Washington Post5d
Nektar: Q3 Earnings Snapshot
SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss ...
Nektar To Sell Manufacturing Facility In Alabama, Reagent Supply Business To Ampersand
(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...
Morningstar7d
Nektar Therapeutics to Participate in Upcoming Investor Conferences
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...